Evan Feinberg, Genesis Therapeutics CEO (Nancy Rothstein Photography)

Gilead part­ners with AI start­up Gen­e­sis Ther­a­peu­tics to make small mol­e­cule drugs

A well-fund­ed Cal­i­for­nia biotech start­up us­ing AI to de­sign and im­prove small mol­e­cule drug can­di­dates has just struck its third phar­ma part­ner­ship in four years …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA